{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:21:55Z","timestamp":1790821315090,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01216-0","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:01:57Z","timestamp":1787302917000},"page":"1330-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rewiring immunity with in vivo CAR T cell engineering"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-6115","authenticated-orcid":false,"given":"Clare Y.","family":"Slaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-7600","authenticated-orcid":false,"given":"Kevin","family":"Sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-3308","authenticated-orcid":false,"given":"Colin W.","family":"Pouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Kershaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-9561","authenticated-orcid":false,"given":"Phillip K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","volume":"21","author":"JD Chan","year":"2021","unstructured":"Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769\u2013784 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 8, 924\u2013934 (2018).","journal-title":"Cancer Discov."},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/cgt.2014.78","volume":"22","author":"AD Kaiser","year":"2015","unstructured":"Kaiser, A. D. et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 22, 72\u201378 (2015).","journal-title":"Cancer Gene Ther."},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N. Engl. J. Med. 392, 677\u2013685 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1216_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, e2304378 (2024).","journal-title":"Small"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"1216_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1216_CR12","doi-asserted-by":"publisher","unstructured":"Su, F. Y. et al. Antigen-specific T cell immunotherapy by in vivo mRNA delivery. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.10.29.620946 (2024).","DOI":"10.1101\/2024.10.29.620946"},{"key":"1216_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4218","volume":"43","author":"TG Humphries","year":"2025","unstructured":"Humphries, T. G. et al. A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma. J. Clin. Oncol. 43, TPS4218 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1216_CR14","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2024-207566","volume":"144","author":"V Lemgart","year":"2024","unstructured":"Lemgart, V. et al. In vitro and in vivo activity of a lipid nanoparticle system for the in vivo generation of CAR T cells. Blood 144, 3421 (2024).","journal-title":"Blood"},{"key":"1216_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.709512","volume":"9","author":"Y Ma","year":"2021","unstructured":"Ma, Y. et al. A comprehensive overview of circRNAs: emerging biomarkers and potential therapeutics in gynecological cancers. Front. Cell Dev. Biol. 9, 709512 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1216_CR16","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell Rep. Med. 6, 102250 (2025).","DOI":"10.1016\/j.xcrm.2025.102250"},{"key":"1216_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep. Med. 6, 102209 (2025).","journal-title":"Cell Rep. Med."},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","volume":"26","author":"E O\u2019Leary","year":"2025","unstructured":"O\u2019Leary, E., Jiang, Y., Kristensen, L. S., Hansen, T. B. & Kjems, J. The therapeutic potential of circular RNAs. Nat. Rev. Genet. 26, 230\u2013244 (2025).","journal-title":"Nat. Rev. Genet."},{"key":"1216_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao, G., Zhang, Y., Xu, C. F. & Wang, J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci. Bull. 69, 354\u2013366 (2024).","journal-title":"Sci. Bull."},{"key":"1216_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-026-00905-3","volume":"14","author":"S Liang","year":"2026","unstructured":"Liang, S. et al. T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy. Biomark. Res. 14, 30 (2026).","journal-title":"Biomark. Res."},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","volume":"34","author":"R Tenchov","year":"2023","unstructured":"Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941\u2013960 (2023).","journal-title":"Bioconjug. Chem."},{"key":"1216_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. 25, 116\u2013137 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1216_CR23","doi-asserted-by":"crossref","unstructured":"Bimbo, J. F. et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J. Immunother. Cancer 13, e011759 (2025).","DOI":"10.1136\/jitc-2025-011759"},{"key":"1216_CR24","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton, J. R. et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. 42, 1684\u20131692 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1216_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","volume":"652","author":"WA Nyberg","year":"2026","unstructured":"Nyberg, W. A. et al. In vivo site-specific engineering to reprogram T cells. Nature 652, 712\u2013721 (2026).","journal-title":"Nature"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li, Y. R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725\u2013744 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. In vivo CAR T cells move into clinical trials. Nat. Rev. Drug Discov. 23, 727\u2013730 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1216_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41434-020-00193-y","volume":"28","author":"IJC Dautzenberg","year":"2021","unstructured":"Dautzenberg, I. J. C., Rabelink, M. & Hoeben, R. C. The stability of envelope-pseudotyped lentiviral vectors. Gene Ther. 28, 89\u2013104 (2021).","journal-title":"Gene Ther."},{"key":"1216_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2013-11-540641","volume":"123","author":"F Amirache","year":"2014","unstructured":"Amirache, F. et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 123, 1422\u20131424 (2014).","journal-title":"Blood"},{"key":"1216_CR30","doi-asserted-by":"crossref","unstructured":"Arduini, A., Katiyar, H. & Liang, C. Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery in vivo. Viruses 17, 802 (2025).","DOI":"10.3390\/v17060802"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","volume":"32","author":"N An","year":"2026","unstructured":"An, N. et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nat. Med. 32, 1257\u20131266 (2026).","journal-title":"Nat. Med."},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","volume":"33","author":"JI Andorko","year":"2025","unstructured":"Andorko, J. I. et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol. Ther. 33, 4937\u20134952 (2025).","journal-title":"Mol. Ther."},{"key":"1216_CR33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai, C. J. et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144, 977\u2013987 (2024).","journal-title":"Blood"},{"key":"1216_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/mt.2016.70","volume":"24","author":"O Humbert","year":"2016","unstructured":"Humbert, O. et al. Development of third-generation cocal envelope producer cell lines for robust lentiviral gene transfer into hematopoietic stem cells and T-cells. Mol. Ther. 24, 1237\u20131246 (2016).","journal-title":"Mol. Ther."},{"key":"1216_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/v4010117","volume":"4","author":"AA Albertini","year":"2012","unstructured":"Albertini, A. A., Baquero, E., Ferlin, A. & Gaudin, Y. Molecular and cellular aspects of rhabdovirus entry. Viruses 4, 117\u2013139 (2012).","journal-title":"Viruses"},{"key":"1216_CR36","doi-asserted-by":"publisher","first-page":"e1005641","DOI":"10.1371\/journal.ppat.1005641","volume":"12","author":"RR Bender","year":"2016","unstructured":"Bender, R. R. et al. Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment. PLoS Pathog. 12, e1005641 (2016).","journal-title":"PLoS Pathog."},{"key":"1216_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/gt.2013.23","volume":"20","author":"SR Witting","year":"2013","unstructured":"Witting, S. R., Vallanda, P. & Gamble, A. L. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther. 20, 997\u20131005 (2013).","journal-title":"Gene Ther."},{"key":"1216_CR38","first-page":"5702","volume":"4","author":"AM Frank","year":"2020","unstructured":"Frank, A. M. et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv. 4, 5702\u20135715 (2020).","journal-title":"Blood Adv"},{"key":"1216_CR39","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","volume":"33","author":"T Coradin","year":"2025","unstructured":"Coradin, T. et al. Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector. Mol. Ther. 33, 4953\u20134967 (2025).","journal-title":"Mol. Ther."},{"key":"1216_CR40","doi-asserted-by":"crossref","unstructured":"Huckaby, J. T. et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J. Immunother. Cancer 9, e002737 (2021).","DOI":"10.1136\/jitc-2021-002737"},{"key":"1216_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang, J. H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther. 9, 78 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1216_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11, 119 (2021).","journal-title":"Blood Cancer J."},{"key":"1216_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels, A., Ho, N. & Buchholz, C. J. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol. Ther. 30, 2401\u20132415 (2022).","journal-title":"Mol. Ther."},{"key":"1216_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omtm.2022.09.017","volume":"27","author":"M Horiuchi","year":"2022","unstructured":"Horiuchi, M. et al. Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors. Mol. Ther. Methods Clin. Dev. 27, 272\u2013280 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1216_CR45","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","volume":"74","author":"CY Slaney","year":"2014","unstructured":"Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. Cancer Res. 74, 7168\u20137174 (2014).","journal-title":"Cancer Res."},{"key":"1216_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1216_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab016","volume":"1","author":"AJ Harrison","year":"2021","unstructured":"Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H. & Slaney, C. Y. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunother. Adv. 1, ltab016 (2021).","journal-title":"Immunother. Adv."},{"key":"1216_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1216_CR49","doi-asserted-by":"crossref","unstructured":"Tantalo, D. G. et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J. Immunother. Cancer 9, e002555 (2021).","DOI":"10.1136\/jitc-2021-002555"},{"key":"1216_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fimmu.2018.00070","volume":"9","author":"AJ Oliver","year":"2018","unstructured":"Oliver, A. J. et al. Tissue-dependent tumor microenvironments and their impact on immunotherapy responses. Front. Immunol. 9, 70 (2018).","journal-title":"Front. Immunol."},{"key":"1216_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","volume":"131","author":"EH Pilkington","year":"2021","unstructured":"Pilkington, E. H. et al. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 131, 16\u201340 (2021).","journal-title":"Acta Biomater."},{"key":"1216_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"1216_CR53","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","volume":"20","author":"MZ Chen","year":"2025","unstructured":"Chen, M. Z. et al. A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles. Nat. Nanotechnol. 20, 1273\u20131284 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"1216_CR54","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","volume":"6","author":"W Jing","year":"2025","unstructured":"Jing, W. et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat. Cancer 6, 838\u2013853 (2025).","journal-title":"Nat. Cancer"},{"key":"1216_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski, A. E. et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4. NPJ Vaccines 10, 73 (2025).","journal-title":"NPJ Vaccines"},{"key":"1216_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett, B. et al. Lymphodepletion\u2014an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 14, 1303935 (2023).","journal-title":"Front. Immunol."},{"key":"1216_CR57","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946 (2025).","journal-title":"Nature"},{"key":"1216_CR58","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","volume":"28","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. 28, 2379\u20132393 (2020).","journal-title":"Mol. Ther."},{"key":"1216_CR59","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata, M. et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 7, 1306\u20131319 (2017).","journal-title":"Cancer Discov."},{"key":"1216_CR60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488 (2019).","journal-title":"Cancer Cell"},{"key":"1216_CR61","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/0008-5472.CAN-16-1831","volume":"77","author":"S Mardiana","year":"2017","unstructured":"Mardiana, S. et al. A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res. 77, 1296\u20131309 (2017).","journal-title":"Cancer Res."},{"key":"1216_CR62","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636\u20135646 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1216_CR63","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-16-1860","volume":"23","author":"CY Slaney","year":"2017","unstructured":"Slaney, C. Y. et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res. 23, 2478\u20132490 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1216_CR64","doi-asserted-by":"publisher","first-page":"25229","DOI":"10.1073\/pnas.1904618116","volume":"116","author":"B von Scheidt","year":"2019","unstructured":"von Scheidt, B. et al. Enterotoxins can support CAR T cells against solid tumors. Proc. Natl Acad. Sci. USA 116, 25229\u201325235 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1216_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1157","volume":"9","author":"JD Chan","year":"2020","unstructured":"Chan, J. D. et al. Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells. Clin. Transl. Immunology 9, e1157 (2020).","journal-title":"Clin. Transl. Immunology"},{"key":"1216_CR66","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"1216_CR67","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"1216_CR68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"1216_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"D Meyran","year":"2023","unstructured":"Meyran, D. et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci. Transl. Med. 15, eabk1900 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1216_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319856121","volume":"121","author":"CM Tilsed","year":"2024","unstructured":"Tilsed, C. M. et al. IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. Proc. Natl Acad. Sci. USA 121, e2319856121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1216_CR71","doi-asserted-by":"crossref","unstructured":"Michels, K. R. et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J. Immunother. Cancer 11, e006292 (2023).","DOI":"10.1136\/jitc-2022-006292"},{"key":"1216_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom, A. et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials 281, 121339 (2022).","journal-title":"Biomaterials"},{"key":"1216_CR73","doi-asserted-by":"crossref","unstructured":"Harrison, S. et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood 146, LBA-1 (2025).","DOI":"10.1182\/blood-2025-LBA-1"},{"key":"1216_CR74","doi-asserted-by":"publisher","first-page":"1750.1","DOI":"10.1182\/blood-2024-208461","volume":"144","author":"J Garcia","year":"2024","unstructured":"Garcia, J., Dehner, C., Teoh, J. & Wallis, W. A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies. Blood 144, 1750.1 (2024).","journal-title":"Blood"},{"key":"1216_CR75","doi-asserted-by":"publisher","unstructured":"Chen, X.-F. et al. 1482 In-vivo CAR-T cells produced by specific virus in refractory B cell lymphoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1482 (2024).","DOI":"10.1136\/jitc-2024-SITC2024.1482"},{"key":"1216_CR76","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2025.43.16_suppl.2591","volume":"43","author":"CR Lemech","year":"2025","unstructured":"Lemech, C. R. et al. First-in-human mRNA CAR therapy: correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors. J. Clin. Oncol. 43, 2591 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1216_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-025-01330-w","author":"HC Geisler","year":"2026","unstructured":"Geisler, H. C., Battistini, E., Thatte, A. S., Padilla, M. S. & Mitchell, M. J. Preparation of targeted lipid nanoparticles for precision nucleic acid delivery. Nat. Protoc. https:\/\/doi.org\/10.1038\/s41596-025-01330-w (2026).","journal-title":"Nat. Protoc."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01216-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:02:07Z","timestamp":1790172127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01216-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":77,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01216-0","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}